Wells Fargo & Company Cuts Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target to $30.00

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price target trimmed by Wells Fargo & Company from $34.00 to $30.00 in a research report sent to investors on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other research analysts also recently issued reports on AMPH. Barclays began coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 price objective on the stock. Zacks Research downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 14th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research report on Monday, December 29th. Finally, Needham & Company LLC reduced their target price on Amphastar Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday. Two investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $29.50.

Amphastar Pharmaceuticals Trading Down 23.6%

Shares of NASDAQ:AMPH opened at $20.23 on Friday. The company has a market capitalization of $917.84 million, a PE ratio of 9.97, a P/E/G ratio of 3.69 and a beta of 0.93. The company has a current ratio of 4.02, a quick ratio of 2.90 and a debt-to-equity ratio of 0.77. Amphastar Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $31.26. The business’s fifty day simple moving average is $27.23 and its 200-day simple moving average is $26.96.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.73 earnings per share for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.24). Amphastar Pharmaceuticals had a net margin of 13.63% and a return on equity of 17.58%. The company had revenue of $183.11 million for the quarter, compared to the consensus estimate of $190.48 million. As a group, equities research analysts predict that Amphastar Pharmaceuticals will post 3.49 earnings per share for the current fiscal year.

Insider Transactions at Amphastar Pharmaceuticals

In related news, Director Floyd F. Petersen sold 2,426 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $25.92, for a total transaction of $62,881.92. Following the completion of the transaction, the director directly owned 71,368 shares in the company, valued at approximately $1,849,858.56. This trade represents a 3.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Rong Zhou sold 9,787 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $26.20, for a total value of $256,419.40. Following the completion of the transaction, the executive vice president directly owned 138,043 shares of the company’s stock, valued at $3,616,726.60. The trade was a 6.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,950 shares of company stock worth $363,925 in the last 90 days. Company insiders own 27.10% of the company’s stock.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 24.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after acquiring an additional 435 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Amphastar Pharmaceuticals by 46.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after purchasing an additional 437 shares during the last quarter. ProShare Advisors LLC raised its stake in Amphastar Pharmaceuticals by 5.3% in the 4th quarter. ProShare Advisors LLC now owns 9,083 shares of the company’s stock valued at $243,000 after purchasing an additional 457 shares during the last quarter. Los Angeles Capital Management LLC lifted its holdings in Amphastar Pharmaceuticals by 2.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 19,397 shares of the company’s stock valued at $478,000 after purchasing an additional 459 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in Amphastar Pharmaceuticals by 37.8% during the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock worth $45,000 after purchasing an additional 462 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

More Amphastar Pharmaceuticals News

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Management expects mid- to high-single-digit revenue growth for 2026 and is launching a new respiratory product, which provides a clear growth runway beyond the quarter that disappointed investors. Amphastar outlines mid- to high-single-digit revenue growth for 2026 while launching new respiratory product
• Positive Sentiment: Two sell-side shops lowered price targets from $34 to $30 but retained constructive ratings (Wells Fargo: overweight; Needham: buy), signaling that analysts still see significant upside from current levels despite trimming near-term assumptions. Analyst price target coverage
• Neutral Sentiment: Company published its Q4 press release, slide deck and conference call materials for investors to review detailed results and management commentary. These materials may clarify margin drivers and product cadence. Press release / slide deck
• Neutral Sentiment: Analyst and media write-ups (Zacks, Seeking Alpha, Investing.com) provide deeper metric-level analysis comparing results to estimates — useful for modeling but not new catalyst by itself. Zacks comparison of key metrics
• Negative Sentiment: Q4 results missed consensus: adjusted EPS of $0.73 vs. ~$0.97 expected and revenue of $183.1M vs. ~$190.5M, prompting investor concern about near-term growth and profit leverage. MarketBeat earnings summary
• Negative Sentiment: Market reaction has been amplified by heavy trading and coverage noting the miss; short-interest reports in public feeds are noisy/unclear but the immediate selloff reflects disappointment with the quarter. Yahoo finance: earnings miss and market reaction

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.